Ipca Laboratories Limited (BOM:524494)
1,512.90
-59.00 (-3.75%)
At close: May 29, 2026
Ipca Laboratories Revenue
In the fiscal year ending March 31, 2026, Ipca Laboratories had annual revenue of 98.21B INR with 9.84% growth. Ipca Laboratories had revenue of 24.82B in the quarter ending March 31, 2026, with 10.40% growth.
Revenue
98.21B
Revenue Growth
+9.84%
P/S Ratio
3.94
Revenue / Employee
5.85M
Employees
16,778
Market Cap
386.75B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 98.21B | 8.80B | 9.84% |
| Mar 31, 2025 | 89.41B | 12.35B | 16.03% |
| Mar 31, 2024 | 77.06B | 14.58B | 23.33% |
| Mar 31, 2023 | 62.48B | 4.18B | 7.16% |
| Mar 31, 2022 | 58.31B | 4.10B | 7.56% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Dr. Reddy's Laboratories | 335.93B |
| Lupin | 279.58B |
| Jubilant Pharmova | 82.80B |
| Abbott India | 69.29B |
| Granules India | 53.66B |
| J. B. Chemicals & Pharmaceuticals | 41.48B |
| GlaxoSmithKline Pharmaceuticals | 38.22B |
| Viyash Scientific | 34.20B |
Ipca Laboratories News
- 5 hours ago - Ipca Laboratories Quarterly report: Q4 2026 - Filings
- 2 months ago - Top stocks to buy: Stock recommendations for March 30, 2026 week - check list - The Times of India
- 2 months ago - Top stocks to buy: Stock recommendations for March 23, 2026 week - check list - The Times of India
- 3 months ago - Ipca Laboratories Transcript: Q3 25/26 - Transcripts
- 3 months ago - Ipca Laboratories Quarterly report: Q3 2026 - Filings
- 3 months ago - Ipca Laboratories Q3 Results: Net profit jumps 31.5% YoY to Rs 326.27 crore, revenue up 6.55% - Business Upturn
- 4 months ago - Ipca Laboratories receives US FDA VAI status for Tarapur API facility - Business Upturn
- 6 months ago - This brokerage firm advises to Buy IPCA Labs shares and expects nearly 20% upside in stock price - Business Upturn